Chao Liang

Identification of Capsazepine as a Novel Anti-Silicosis Agent via TRPV1/PI3K/AKT Axis Inhibition.

This study is the first to demonstrate that CPZ is a candidate anti-silicosis drug with clinical translational potential, offering a new theoretical and experimental basis for targeted silicosis therapy.